# A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer

> **NCT01904318** · PHASE1 · COMPLETED · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** IDP-73152 mesylate 40 mg
- **DRUG:** IDP-73152 mesylate 80 mg
- **DRUG:** IDP-73152 mesylate 160 mg
- **DRUG:** IDP-73152 mesylate 320 mg
- **DRUG:** IDP-73152 mesylate 640 mg
- **DRUG:** IDP-73152 mesylate 1280 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01904318
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01904318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01904318, "A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01904318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*